Results suggest a possible link between genomic instability and iciHHV-6 associated disease.
MS drug teriflunomide dramatically reduces antibody titers to EBV and HHV-6
Study results are consistent with a pathogenetic role for viruses in relapsing-remitting MS.
Synergistic role of HHV-6A U37 and heat shock proteins in viral replication
Findings provide important insights that may reveal potential targets for antiviral therapy.
Growing evidence of rare HHV-7 associated encephalitis and seizures in the immunocompetent
The clinical picture is very similar to HHV-6B encephalitis.
Strong Evidence Linking HHV-6B To Pneumonia in Transplant Patients
Levels of mRNA transcripts indicating active infection strengthen case for pathogenic role.
New Evidence that HHV-6A, like EBV, May Trigger Some Cases of Multiple Sclerosis (MS)
Sera drawn before vs. after onset of MS find seropositivity for HHV-6A more likely in MS.
Substituting letermovir for broad-spectrum ganciclovir for CMV prophylaxis did not increase HHV-6 disease in allogenic transplant patients
Investigators were surprised that the use of the less toxic CMV specific antiviral did not result in a significant increase in HHV-6-related disease.
Meta-Analysis links EBV, HHV-6 and VZV to multiple sclerosis
Study pools data from nearly 30,000 people with MS.
International expert panel publishes guidelines for management of DRESS
Guidelines recommend routinely assessing HHV-6 viral load, but not antiviral treatment when HHV-6 reactivation identified.
HHV-6 detectable in some urine samples, but not linked to disease
In contrast, human papillomavirus found more often in urine of bladder cancer patients than in urine of patients with non-cancerous urinary tract conditions.
Higher HHV-6 viral load in oral mucosa cells in people with major depression
Combination of viral load and presence of specific polymorphism in the TNF-α gene associated with major depression.
Phase III trials suspended for T-cell therapeutic active against HHV-6
In a surprise, multi-virus cytotoxic T cell therapy trials were terminated early for failure to meet endpoints.
Part 1: Latent HHV-6 is reactivated in patients receiving CAR-T cell therapy
Investigators urge careful monitoring for HHV-6 and ciHHV-6.
Part 2: CAR-T cell therapy and its complications
Could some complications of CAR-T cell therapy be secondary to HHV-6 infection?
Part 3. HHV-6 Encephalitis in CAR-T Cell therapy
Clearly documented cases of HHV-6 encephalitis have been reported, but some are missed because they were classified as ICAN or because HHV-6 testing was not performed in patients with mental status changes.